and of subtelomeric anomalies, we give evidence that microrearrangements could be a major molecular mechanism in HPE. Additionally, this study opens new insights on HPE candidate genes identification giving an updated HPE candidate loci map.
Aetiology includes karyotype anomalies, environmental factors and genic forms that can be syndromic or isolated. Non-random structural chromosomal anomalies previously compiled from chromosomal HPE predicted at least 12 different HPE loci.
To date, eight HPE genes have been identified from recurrent chromosomal rearrangements or from the sequencing of genes from Nodal and SHH pathways.
Our cohort of isolated HPE presents a high genetic heterogeneity. Point mutations were found in SHH, ZIC2, SIX3 and TGIF genes in about 20% of cases (with 10% in SHH) . Submicroscopic deletions in these same genes were found in 7.5% and 4.4%
presented with other subtelomeric gain or losses. Consequently molecular basis of HPE remains unknown in 70% of our cohort.
In order to detect new HPE candidate genes, we used array-CGH to refine the previous karyotype based HPE loci map. We analysed 111 HPE patients with high performance Agilent arrays made of 44K or 244K oligonucleotidic probes and found that 28 presented with submicroscopic anomalies involving known or new potential HPE loci located on different chromosomes but with poor redundancy. We observed 14 isolated deletions, 9 isolated duplications and 5 associated genomic losses and gains. Compiling these new data with frequencies of deletions in known HPE genes and of subtelomeric anomalies, we give evidence that microrearrangements could be a major molecular mechanism in HPE. Additionally, this study opens new insights on HPE candidate genes identification giving an updated HPE candidate loci map. associated with facial anomalies. HPE is a severe pathology, associated with mental retardation in all affected live newborns, with poor or symptomatic treatment (Cohen, 2006) . The genetic counselling in HPE families is very complex due to the extreme phenotypical variability, the genetic heterogeneity, and a high recurrence risk (13%)
in apparently sporadic cases. Chronologically, non-random structural chromosomal anomalies previously compiled from chromosomal HPE predicted at least 12 different HPE loci, and out of these 12 loci, eight genes have been really implicated in HPE with mutations found in isolated HPE: Sonic hedgehog (SHH; 7q36; HPE3) ], ZIC2 (13q32; HPE5) (Brown, et al., 1998) , SIX3 (2p21; HPE2) (Wallis and Muenke, 1999) , TGIF (18p11.3; HPE4) (Gripp, et al., 2000) , PATCHED1 (9q22) (Ming and Muenke, 2002) , TDGF1 (3p21.31) (de la Cruz, et al., 2002) , FAST1 (8q34) (Ouspenskaia, et al., 2002) and GLI2 (2q24) (Roessler and Muenke, 2003) . In total, these actors play a role either in the SHH pathway, or in the Nodal/Transforming Growth Factor beta (TGFβ) pathway, or as transcription factors.
Point mutations in the four major genes, SHH, ZIC2, SIX3 and TGIF, were identified in 20% of our HPE patients. Among these genes, SHH appears to be the major one accounting for 50% of the identified mutations (Dubourg, et al., 2004) . Animal studies and rare human cases showed that double heterozygous mutations could be involved in HPE phenotype, introducing the multi-hit hypothesis in this developmental disorder (Ming and Muenke, 2002) . This hypothesis helped in the understanding of the variable penetrance of familial mutations in the disease and led us to systematically screen the four genes, even if one mutation was initially found in the first sequenced gene. Additional work is focusing on environmental factors including low cholesterol levels (Edison, et al., 2007) .
Since 2003, we also screened these genes for microrearrangements and proved for the first time the implication of gene deletions in 7.5% in holoprosencephaly (3.2% in F o r P e e r R e v i e w SHH, 2% in ZIC2, 1.6% in SIX3 and 0.65% in TGIF) (Bendavid, et al., 2006a; Bendavid, et al., 2006b) . When comparing the combined mutation and deletion results observed in the foetus cohort and in the live-born children, the total proportions of gene anomalies are close (28% and 24% respectively), but the rate of point mutations is much higher in live born children than in foetuses (23% versus 14%) whereas submicroscopic deletions, which represent gross alterations, occur more frequently in foetuses (10% versus 5%) who generally have a more severe phenotype.
Because of the HPE clinical and genetic heterogeneity, and the lack of informative families, a classical positional cloning strategy based on genome wide scan is not possible. Consequently, we were led to develop a strategy based on molecular biology and cytogenetics to identify candidate regions and thus candidate genes.
This approach will complete the initial karyotype based study of recurrent chromosomal abnormalities which led to the identification of the first HPE genes and HPE loci map (Roessler and Muenke, 1998) .
After screening of microdeletions or mutations in known HPE genes with QMPSF/MLPA or DHPLC plus sequencing respectively, we searched for submicroscopic rearrangements in subtelomeric chromosomal regions using the Multiplex Ligation Probe Amplification (MLPA) method (Hogervorst, et al., 2003) .
Indeed, subtelomeric aberrations were detected in 4,4% of our HPE patients with no known anomaly, showing either a single anomaly or an association between a deletion and a gain, these rearrangements were very heterogeneous, encompassing 10 different subtelomeric regions. Some targeted regions known to be implicated in HPE (7q encompassing the SHH gene, 18p encompassing the TGIF gene, 21q
including a candidate gene, LSS (Lanosterol Synthase)), but also new regions (1p, 5q, 7p, 8p, 9q, 17q, 18q and 22q) were identified. Several samples, mainly foetal ones, consisted of an association between a duplication and a deletion in two chromosomal subtelomeres like (dup7pter; del7qter) or (dup20pter; del21qter).
Moreover, rearrangements presented by foetuses generally implied known HPE loci, while those observed in live children encompassed regions not previously described . But, even if we compile these large deletions, point mutations and deletions in the known genes, the combined rate of patients with identified molecular basis only reaches 30%, so more than 70% of the cases remain Confirming the growing importance of micro rearrangements, this study showed up an impressive rate of 28 patients among 111 with submicroscopic chromosomal anomalies. These defects involved known or new potential HPE loci located on different chromosomes but with poor redundancy. Added to the previous microdeletion findings in known HPE genes and subtelomeres, our data showed that microrearrangements could be the major molecular mechanism in HPE and strongly reinforce the multigenic origin in this developmental disorder.
MATERIAL AND METHODS

Patients and controls
The cohort consisted in 9 patients presenting with a known deletion already detected by qPCR or QMPSF in HPE genes (SHH, TGIF, ZIC2 and SIX3) This study was approved by the Institutional Review Board, and parents of all participants gave their informed consent.
Comparative Genomic Hybridization study
Briefly, for live-born children, genomic DNA was extracted from peripheral whole blood by the Flexigene DNA kit from QIAGEN. For foetuses, DNA was extracted from tissues or cultured amniotic cells, using the QIAamp DNA minikit from QIAGEN. DNA concentration was determined using a NanoDrop Spectrophotometer (NanoDrop Technologies, Inc., Wilmington, DE).
Array-CGH analysis can be hampered by the large DNA input requirement: a minimum of 0.5 µg per sample are needed to process one array-CGH. Most of our samples were extracted from foetuses, and only a small amount of DNA is often available. So, when necessary, DNA samples were amplified using a whole genome amplification method. In this case, control DNA was also amplified in order not to cohybridize a native DNA from a control with an amplified DNA from a patient. Array-CGH Array-CGH was performed using the Agilent Human Genome Microarray Kit 44A and 244A (Agilent Technologies, Santa Clara, CA, USA). These are high resolution 60-mer oligonucleotide based microarrays containing 44,000 or 244,000 60-mers probes respectively, spanning coding and non-coding genomic sequences with median spacing of 24 kb and 7.4 kb respectively.
DNA amplification
When using native DNA, both patient and a sex-matched control's DNAs were separately digested with both AluI and RsaI (Promega, Madison, WI, USA) for 2 h at 37C°. Quality of digestion was controlled on a 1% agarose gel.
When patient and control DNA were amplified digestion was not necessary as the WGA method already generates small fragments, and DNA was directly labelled after purification. 
Bioinformatics
Data were imported into Agilent CGHanalytics software version 3.4.27 for analysis.
Identification of probes with a significant gain or loss was based on cut-off values of 0.5 and -1 respectively. Based on CGHanalytics Quality control metrics (QCmetrics), the arrays included had a Derivative Log Ratio (DLR) spread score under 0,320. The DLR Spread metrics estimates the log ratio noise by calculating the spread of log ratio differences between consecutive probes along all chromosomes (Largo, et al., 2007) . DNA sequence information from the software was linked to the public UCSC database (Human Genome Browser, May 2004 Assembly: Hg18). We only conserved gains or losses that encompassed at least 3 consecutive spots on the array. We didn't present in the result table the gains and losses corresponding to high frequency copy number variation (CNV).
Based on a quality score for the arrays, we classified them in two groups so that to select arrays that could enter a transversal analysis using the Nexus Copy Number software (www.Biodiscovery.com). Patient CGH files extracted from Feature extraction were uploaded into the Nexus Copy Number software. This software also gives a quality score: all arrays with a score under 0.180 (corresponding to 0.320 in CGH analytics) allowed the transversal analysis without strong interfering background (that could generate false positive gains or losses). Using this transversal analysis, we compiled all array data and gave a graphic view of the combined results (aggregate) where the frequencies of anomalies were represented by histograms. This aggregate easily pointed out small redundant rearrangements that resulted either from frequent CNV either from one anomaly of the control DNA (mirror image in most of the patients). Finally, all gains or losses could be compared to CNV listed in the database (monthly updated from TCAG) and exported in Tables   (Tables 1, 2 The aim of this approach was to detect the redundancy of small regions and get a percentage value to compare with rare CNV frequencies for the same area when such CNV was already described in databases (TCAG human variation website:
http://projects.tcag.ca/variation/). 
RESULTS
Search for CNVs in control DNA
Male and female control DNAs were co-hybridized on a 244K microarray in order to better characterize copy number variants (CNV) that could be present even in these phenotypically normal individuals.
Gains or losses observed in the two control genomic DNA were listed in order to be taken into account in the interpretation of patients' array-CGH results (data not shown).
Array-CGH analysis in patients
120 patients (70 foetuses and 50 live-born children) were analysed either on a 44K or a 244K Agilent oligonucleotide arrays.
Out of them, 9 presented with a known deletion already detected by qPCR or QMPSF on known genes (SHH, TGIF, ZIC2 and SIX3) or subtelomeric rearrangements shown by MLPA experiments. They were analysed on 44K arrays.
A first cohort of 37 patients without any karyotypic alterations was also tested with 44K agilent array-CGH and another cohort of 74 HPE patients was secondarily tested on 244K array-CGH as soon as this platform became commercially available.
Patients with known rearrangements
Out of the 9 patients with known rearrangements analysed on 44K arrays, 7 were foetuses and 2 were live born children. 7 had severe HPE phenotype with alobar or semilobar form. These patients were known to present deletions in known genes like SHH, TGIF, ZIC2 and SIX3, but array-CGH analysis could give the size of the losses which ranged from 1 gene to 30Mb, and showed that 4 of them had also gain of genomic DNA.
An overview of all imbalances is shown in Table 1 .
Patients analysed on 44K arrays
A first array-CGH analysis on 37 HPE patients was performed, using oligonucleotide 44K Agilent® array. 19 cases were foetuses and 18 were live-born children. Sub microscopic chromosomal imbalances were detected in 9 (5 fetuses, 4 children) out 
Patients analysed on 244K arrays
Another cohort of 74 HPE (45 foetuses and 29 live-born children) was then analysed, using a higher resolution array (244K Agilent®).
19 patients (12 fetuses, 7 children) out of 74 (26%) presented copy number variations not described in the CNV databases. These rearrangements are more frequently deletions as 12 patients had an isolated or associated loss. 11 patients had isolated or associated duplications. The size's range of the imbalances is very large, from 300
Kb to 16.5 Mb (Table 3) .
Nexus study
Compiling 90 
DISCUSSION
This study is the first series of HPE patients to be screened for chromosomal imbalances with high resolution oligonucleotide microarrays. In a total of 111 patients with normal karyotype, 28 were detected with chromosomal imbalances (25%). This unexpected high frequency, whatever the size, location and redundancy of the rearrangements, demonstrates that CGH is mandatory to detect submicroscopic molecular defects; consequently, adding these anomalies to the results of the classic diagnosis screening of isolated HPE, the rate of identified molecular defects could exceed for the first time 50% of cases.
Methodology
Control DNA
We decided to use genomic DNA from one normal male 46,XY and one normal female 46,XX as controls. Indeed, it seemed to us that it was easier to validate the CNVs status of these two DNA samples and thus avoid false positive or negative results in our series. A similar strategy was chosen by Carter et al (Carter, 2007) , (Figure 1 ) whose embryonic expression pattern in the mouse orthologue is compatible with a role in holoprosencephaly (Maas, et al., 2007) . This gene contains a nested gene in its third exon, called FLRT3, coding a fibronectin leucinrich repeat transmembrane protein, which could be a conserved Nodal target.
Indeed, loss of function in the FLRT3 gene leads to defects in ventral closure, headfold fusion and definitive endoderm migration (Maretto, et al., 2008) . (Maas, et al., 2007) .
To confirm that the rearrangements observed in our 4 patients were not benign CNV, the different database reporting these large-scale polymorphisms were investigated and unlike the Maas paper data, we could determine that they overlapped described CNVs. Moreover, Kuniba et al recently described the results of a deletion assay for the exon 5 in MACROD2 and a mutation analysis of MACROD2 and FLRT3 among 43 patients with KS in Japan (Kuniba, et al., 2008) . They also showed that 2 patients out of 18 presented copy number variations in this region, and concluded that MACROD2 and/or FLRT3 could not be the causative gene in most Japanese KS patients.
These two papers and our own analysis demonstrate that one should be very cautious about the involvement of genes in diseases without an achieved CNV database to analyze the results.
Minimal size to be considered
Currently available data suggest using a DNA size cut-off for a positive result. To avoid listing many anomalies (small CNV or background noise related to one or two consecutive spots on the array), we chose that all data presented in tables must result from three consecutive co-deleted or co-duplicated probes on the 44K or 244K
arrays to produce strong evidence of any genomic defect; consequently their respective resolution can be estimated to 48kb and 14.8kb respectively.
This compromise is not perfect as this cut-off of 3 spots on the 44K array would have led us to discard a deletion located only on SIX3 gene (Table 1 ) and involving only one spot, if we had not been aware of its existence based on previous specific studies (Bendavid, et al., 2006a) .
Impact of array resolution
We used the oligonucleotide 44K Agilent® arrays to test 37 HPE patients (19 foetuses and 18 live-born children). Sub microscopic chromosomal imbalances were detected in 9 out of them (24%), 6 deletions and 4 duplications ( When using the high resolution arrays, the rate of detected rearrangements modestly raises (26% versus 24%). This suggests that the resolution of the 44K arrays could be sufficient for routine screening of HPE patients. On the opposite, the higher rate of small deletions detected by 244K needs more data compiling (based on Nexus software to point out the more frequent anomalies and exclude putative CNV). In routine diagnosis, the cost of the 244K array versus its modest raise of the detection rate could certainly limit the CGH approach to the 44K array.
Patient's results
Identified loci were heterogeneous in size and poorly redundant, but large anomalies were preferentially found in fetuses
Previous data suggested that deletions in known genes (SHH, SIX3, ZIC2 and TGIF)
were more frequent in foetuses than in children, who, on the opposite, presented a higher rate of mutations (Bendavid, et al., 2006a; Bendavid, et al., 2006b ). The present study corroborates this hypothesis as 17 chromosomal rearrangements were observed in foetuses (61%) versus 11 in children (39%).
The structural variations observed in our cohort present a wide range of sizes.
We first determined the precise size of rearrangements in samples known to be deleted for HPE genes (SHH, TGIF, SIX3 and ZIC2) by qPCR, QMPSF or MLPA or by high resolution karyotype (Table 1 ). The patient (N°8) with a deletion of TGIF in 18p shown by quantitative PCR (Bendavid, et al., 2006a) had in fact a 10 Mb loss of telomeric genomic DNA. Deletions in 13q including ZIC2 ranged from 1.7 Mb to 30.7
Mb, while those including SHH in 7q ranged from 3 Mb to 7 Mb. The severity of the phenotype seems to be correlated with the size of the deletion, if we consider that wider rearrangements are mostly found in foetuses with alobar or semi-lobar HPE, while the smaller ones (even concerning a single probe like the patient (N°1) with isolated SIX3 deletion) were preferentially observed in live-born children, with lobar HPE accompanied with minor signs. Nevertheless, phenotype/genotype correlation is not straight as children with typical HPE do not have a higher rate of rearrangements than children with minor signs. 
Parental analysis
In our series, out of 28 patients with gains or losses, both parents could be tested in 21 cases (focusing on 26 rearrangements). The aim of this parental analysis was to further modulate the role of these rearrangements in phenotype onset based on their inheritance.
Therefore, we postulated first that all anomalies found isolated (not associated with a mutation) and that raised de novo in the proband would be the more likely to be involved in the phenotype. Second, all anomalies found isolated but inherited from one parent would be part from a genetic background and may only act with a variable penetrance or with an associated factor. Finally, if found associated with a mutation and inherited from one parent, the anomaly would more likely be a very minor modulator.
In our series, 9 patients had at least one gain or loss inherited from one parent; 8
were duplications whereas only 3 were deletions (patients N° 23, 30 and 32). In 6 patients (N° 18, 21, 27, 30, 32 and 37), rearrangements were associated to mutations. Therefore, no definitive conclusion about the involvement of these different regions can be given.
On the opposite, out of the 11 patients with de novo gains or losses, we had 9 deletions and only 4 duplications. 8 involved known HPE loci: 2p (SIX3), 7qter
(SHH), 13q (ZIC2), 18pter (TGIF), 20pter and 21qter. This reinforces the implication of loci like 20pter or 21qter in HPE but also gives new candidate loci with regions not previously involved in the disease: 1q, 6q, 7p, 10q, 14q and 17q. The 14q del was already reported by Kamnasaran et al in 2005 as a putative HPE loci (Kamnasaran, et al., 2005) . The two overlapping 6q del are also particularly interesting as they mapped a new locus that appeared twice de novo.
It's worth noting that one patient (N°25) presents a SHH locus duplication. This could be associated with a SHH gain of function, what has never been described before in HPE. Nevertheless, this defect was also found in the mother (normal phenotype).
SHH gains of function are usually associated with basocellular carcinoma that have not been described to date in this family. On another hand, this rearrangement may cause a SHH loss of function based on the modification of the chromatin environment. Further investigations on SHH expression in this family should be overtaken. and the deletion was inherited from the father, knowing that furthermore the father also transmitted a SHH mutation. Another case (N°27) with no parental study also had an associated SHH mutation. Consequently, a role for PATCHED3 is questionable and it's difficult to consider it as a strong modulator making the fetus phenotype worse than his father's.
CGH use in routine diagnosis
For diagnosis, this study demonstrates that the CGHarray approach must be another part of the molecular routine so that to get as much potential markers of the disease as possible to help the genetic counseling. In our experience, this method has been very helpful in the identification of unbalanced subtelomeric anomalies (as MLPA for subtelomeres but with the advantage of determining the breakpoints in the same time) and led to identification of parental cryptic balanced translocations by FISH. Roessler et al (1998) and 14q loci from Kamnasaran and al (2005) papers. 2) in green all gains found in our cohort 3) in red all losses found in our cohort. Gains and losses are associated with the patient numbers that can be found in tables 2, 3 and 4. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 
